HomeInvestors & MediaNews
- ABL to announce preclinical results for ABL301, the leading BsAb targeting α-synuclein with BBB shuttle (Grabody-B)
- ABL’s novel IGF-1 Receptor-based shuttle (Grabody-B) mediates efficient delivery of biologics across the blood-brain barrier with outstanding PK profiles in primate study
March 9, 2021 - ABL Bio, Inc., a South Korean biotech developing bispecific antibody technology for immuno-oncology and neurodegenerative diseases, today announced that it will present results from the preclinical study for ABL301 at the 15th International Conference on Alzheimer’s & Parkinson’s Diseases (AD/PD 2021). The presentation will highlight preclinical results demonstrating the efficacy, tolerability and pharmacokinetics of ABL301.
ABL demonstrated insulin-like growth factor 1(IGF1R)’s unexpected role as a target for BBB shuttle of biologics into brains and Grabody-B as a novel BBB shuttle with high efficiency and safety. The major challenge of BBB shuttles is faster clearance of the shuttle-fused bispecific antibody. As a result, shorter PK profile than a therapeutic antibody itself may result in only transient CNS exposure without a sustained BBB penetration. A study with primates suggested Grabody-B’s superior and sustained delivery of ABL301 into the brain with more than 13 times higher BBB penetration levels than a monoclonal antibody. Grabody-B-based ABL301 also achieved significantly higher therapeutic outcomes compared to the therapeutic antibody alone in an animal model of PD due to its elevated CNS exposure.
“We look forward to sharing this new data with worldwide experts in the field,” said ABL Bio. “The presentation highlights the great amount of interest in our ‘Grabody-B’ platform and ABL301 as innovative treatments that overcome the limitations of neurodegenerative disease therapies.”
About ABL Bio
ABL Bio, Inc. (KOSDAQ: 298380) is a South Korean biotechnology company developing antibody therapeutics for immuno-oncology and neurodegenerative diseases. With internal R&D and global partnerships, ABL has developed multiple BsAb platforms, such as ‘Grabody-T,’ ‘Grabody-I’ and ‘Grabody-B’ and built an innovative pipeline of multiple clinical and pre-clinical stage drug candidates. In the oncology area, we have developed Grabody-T, a modular 4-1BB engaging platform that has demonstrated superior efficacy and safety. In the neurodegenerative disorder space, we have developed Grabody-B platform, which is designed to maximize blood-brain barrier(BBB) penetration. Grabody-B is applicable to various CNS targets across a plethora of neurological disorders, potentially providing a breakthrough to address the high unmet medical needs in neurodegeneration. For more information, please visit www.ablbio.com